AbbVie Inc. shares eased about 0.5% in pre-open trading after a bipartisan U.S. House committee, led by Representative John Moolenaar, launched a national security investigation into the company’s drug trials carried out in China. The committee has asked AbbVie to provide documents by July 17 addressing due diligence and data protection practices at trial locations in Xinjiang and at military hospitals.
The probe also targets the peer drugmaker Merck, and lawmakers said the inquiry centers on how clinical trials in China were managed. The committee action has raised concerns about potential regulatory scrutiny and reputational fallout tied to China-based clinical operations, creating a company-specific headwind for AbbVie even as other drivers support the stock.
Offsetting some of the headline pressure, investment bank Piper Sandler reiterated a Buy rating on ABBV today, signaling continued Wall Street confidence in the company’s development pipeline and overall growth trajectory.
AbbVie this week reported a significant late-stage clinical milestone. The company said its Phase 3 EPCORE DLBCL-4 trial met the primary endpoint, with the epcoritamab-plus-lenalidomide combination cutting the risk of disease progression or death by 60% in patients with relapsed or refractory diffuse large B-cell lymphoma. Management characterized this as a clinically meaningful result that strengthens the company’s oncology franchise.
On the regulatory front, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of upadacitinib, marketed as Rinvoq, for the treatment of severe alopecia areata. That recommendation expands the drug’s potential label and supports product lifecycle growth.
The modest pre-market decline follows a sharp rally in AbbVie shares over the prior five sessions, during which the stock climbed roughly 17% to reach a new 52-week high. That recent run was driven in part by AbbVie’s announced acquisition of Apogee Therapeutics for $10.9 billion and a string of favorable regulatory and clinical updates. Given that concentrated advance, some profit-taking was a natural counterforce.
Broader market conditions were supportive on the day, with the S&P 500 up 1.2% and the Nasdaq rising 2.1% after reports of a U.S.-Iran ceasefire agreement that restored risk appetite across sectors. Despite the broader market rally, the House committee investigation represents a company-specific risk that is tempering investor enthusiasm, producing a mild pullback amid an otherwise constructive pipeline and analyst backdrop as market participants close out the first half of the year.
What this means
- The investigation introduces regulatory and reputational uncertainty specific to AbbVie’s China-based clinical activities.
- Robust clinical data and a favorable European regulatory opinion continue to support AbbVie’s product and growth outlook.
- Recent strong price performance and a large corporate deal contributed to a short-term profit-taking dynamic.